Patents Assigned to Arexis AB
-
Patent number: 11180542Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: March 3, 2020Date of Patent: November 23, 2021Assignee: Arexis ABInventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 10625180Abstract: This application is directed to a method of producing vials containing a composition comprising a recombinant protein. In some embodiments, the method comprises: (a) providing a container containing a composition comprising a recombinant protein optionally where the container has been stored under positive pressure; (b) applying a vacuum to the container containing a composition comprising a recombinant protein; (c) allowing the vacuum to degas the composition; and (d) filling vials with the de gassed composition comprising a recombinant protein.Type: GrantFiled: October 30, 2015Date of Patent: April 21, 2020Assignee: Arexis ABInventors: Sureshkumar Choudhary, Tesfu Mezghebe, Mary Houchin, Eric Vernooij, Marjo Peters, Marta Corcoran, Yoen Joo Kim, Mingyan Cao
-
Patent number: 10604560Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: December 22, 2017Date of Patent: March 31, 2020Assignee: Arexis ABInventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 7943338Abstract: The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.Type: GrantFiled: March 8, 2010Date of Patent: May 17, 2011Assignee: Arexis ABInventors: Rikard Holmdahl, Peter Olofsson
-
Patent number: 7872052Abstract: The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruritus, as well as cancer such as ovarian cancer.Type: GrantFiled: June 7, 2004Date of Patent: January 18, 2011Assignee: Arexis ABInventor: Marcel Linschoten
-
Patent number: 7858369Abstract: Transgenic non-human animals that express the ?3 subunit of PRKAG are described, as well as methods of using the transgenic non-human animals as models for improving treatment, prevention, or diagnosis of diseases related to energy metabolism, including obesity, dyslipidemia, insulin resistance syndrome, and type 2 diabetes.Type: GrantFiled: May 4, 2007Date of Patent: December 28, 2010Assignee: Arexis ABInventors: Leif Andersson, Stefan Marklund
-
Patent number: 7476731Abstract: Variants of the ? subunit of AMPK, nucleic acids encoding such variants, and methods for their use are provided.Type: GrantFiled: February 7, 2007Date of Patent: January 13, 2009Assignee: Arexis ABInventor: Göran Hjälm
-
Patent number: 7462693Abstract: Variants of the gamma chain of vertebrate AMP-activated kinase (AMPK), as well as nucleic acid sequences encoding the variants and use thereof for the diagnosis or treatment of dysfunction of energy metabolisms.Type: GrantFiled: January 24, 2007Date of Patent: December 9, 2008Assignee: Arexis ABInventors: Leif Andersson, Christian Looft, Ernst Kalm, Denis Milan, Annie Robic, Claire Rogel-Gaillard, Nathalie Iannuccelli, Joel Gellin, Pascale Le Roy, Patrick Chardon
-
Patent number: 7452982Abstract: The invention relates to an immunogenic complex comprising at a least one glycoside and at least one lipid, integrated into an iscom complex or matrix, and at least one antigen which antigen is integrated into the iscom complex or coupled on to or mixed with the iscom complex or iscom matrix complex, characterised in that it also comprises at least one enzyme. It also relates to such a complex further comprising at least one peptide which specifically binds to a receptor expressed on a cell capable of antigen presentation, which cell expresses MHC Class I or Class II and to compositions comprising the complexes.Type: GrantFiled: October 1, 2001Date of Patent: November 18, 2008Assignee: Arexis ABInventors: Nils Lycke, Kristian Dalsgaard, Allan Mc Mowat, Bjorn Lowenadler, Peter Kaastrup
-
Patent number: 7294652Abstract: The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.Type: GrantFiled: May 13, 2003Date of Patent: November 13, 2007Assignee: Arexis ABInventors: Rikard Holmdahl, Peter Olofsson
-
Patent number: 7214850Abstract: Transgenic non-human animals that express the ?3 subunit of PRKAG are described, as well as methods of using the transgenic non-human animals as models for improving treatment, prevention, or diagnosis of diseases related to energy metabolism, including obesity, dyslipidemia, insulin resistance syndrome, and type 2 diabetes.Type: GrantFiled: January 31, 2003Date of Patent: May 8, 2007Assignee: Arexis ABInventors: Leif Andersson, Stefan Marklund
-
Patent number: 7208305Abstract: Variants of the ? subunit of AMP-activated kinase (AMPK), nucleic acids encoding such variants, and methods for their use are provided. The AMPK variants include splice variants that have an additional exon in the AMPK mRNA, and thus have an additional 15 amino acid residues in the encoded polypeptide. The AMPK variants can, for example, have at least 75% identity to the amino acid sequence of SEQ ID NO:4, and can contain an amino acid sequence having at least 75% identity to the amino acid sequence of SEQ ID NO:2.Type: GrantFiled: January 31, 2003Date of Patent: April 24, 2007Assignee: Arexis ABInventor: Göran Hjälm
-
Patent number: 7148020Abstract: The invention provides methods and materials related to treating and diagnosing autoimmune conditions. Specifically, the invention provides polypeptide compositions, nucleic acids, substantially pure polypeptides, host cells, and methods for identifying a mammal with an autoimmune condition, treating a mammal with an autoimmune condition, and enhancing tolerance in a mammal with an autoimmune condition.Type: GrantFiled: July 11, 2002Date of Patent: December 12, 2006Assignee: Arexis ABInventors: Rikard Holmdahl, Jan Ake Engstrom, Jan Kihlberg, Harald Burkhardt
-
Publication number: 20060147910Abstract: The present invention relates to a polypeptide which is a flavin-containing monooxygenase 3 (FMO3), wherein said FMO3 is a polypeptide comprising at least a sequence having at least 85% identity with the polypeptide sequence SEQ ID NO: 15, in particular to a polypeptide which is a functionally altered mutant of flavin-containing mono oxygenase 3 (FMO3) leading to a buildup of trimethylamine in an animal. Further, the invention relates to nucleic acid sequences encoding said polypeptide, and to the complements of such nucleic acid sequences. Such nucleic acid sequences and fragments thereof may be useful e.g. as primers. The invention further relates to various methods for determining the presence in e.g. a nucleic acid sample of a nucleic acid sequence encoding a mutated FMO3 polypeptide.Type: ApplicationFiled: January 9, 2003Publication date: July 6, 2006Applicant: Arexis AB, a corporation of SwedenInventors: Anne Lunden, Leif Andersson, Stefan Marklund
-
Publication number: 20040121385Abstract: PRKAG3 nucleotide and amino acid sequence variants and methods of detecting such sequence variants are described. Methods for providing risk estimates for development of a metabolic disease also are described and are based on the presence or absence of PRKAG3 sequence variants in a biological sample.Type: ApplicationFiled: November 10, 2003Publication date: June 24, 2004Applicant: Arexis AB, a Swedish corporationInventors: Leif Andersson, L. Holger Luthman, Stefan Marklund
-
Patent number: 6465714Abstract: Congenic animals and animal populations having type II diabetes-associated phenotypes are described. Insulin degradation polypeptides having amino acid substitutions linked to a type II diabetes-associated phenotypes also are described.Type: GrantFiled: November 5, 1999Date of Patent: October 15, 2002Assignee: Arexis ABInventors: L. Holger Luthman, L. G. Joakim Galli